drugset
drugset / Trial / NCT01339299

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

NCT01339299 ↗

Phase 4 Completed 100 enrolled Regionshospitalet Viborg, Skive
RandomizedParallel-groupOpen-labelBasic science

Summary

The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.

Timeline

Start
2009-10
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ovidrel Protein / enzyme biologic 25 iu Subcutaneous
Subject recombinant luteinizing hormone Protein / enzyme biologic 150 iu Subcutaneous

Indications

infertility disorder